Table 2. Evolution of quantitative indicators of macular thickness by OCT in patients with ocular topical treatment of bromfenac 0.09%, nepafenac 0.1% and diclofenac sodium 0.1%.
| Outcomes | Total |
Bromfenac 0.09% |
Nepafenac 0.1% |
Diclofenac sodium 0.1% |
Global P | ||||||||
| Mean | 95%CI lower | 95%CI upper | Mean | 95%CI lower | 95%CI upper | Mean | 95%CI lower | 95%CI upper | Mean | 95%CI lower | 95%CI upper | ||
| Pre-S AT - 3wk | 6 | -11.5 | -5.9 | -12.2 | -18.4 | -6.0 | -7.9 | -12.9 | -2.9 | -6.2 | -9.6 | -2.8 | 0.197 |
| Pre-S AT - 2mo | -12.6 | -16.0 | -9.1 | -16.8 | -24.4 | -9.2 | -12.7 | -19.2 | -6.2 | -8.4 | -11.9 | -5.0 | 0.126 |
| Pre-S CT - 3wk | -5.7 | -14.5 | 3.1 | -21.3 | -40.7 | -1.9 | 6.4 | -7.2 | 20.0 | -1.3 | -13.3 | 10.7 | 0.037 |
| Pre-S CT - 2mo | -15.1 | -26.2 | -4.0 | -35.4 | -61.5 | -9.3 | 5.3 | -9.3 | 19.9 | -11.5 | -24.4 | 1.5 | 0.015 |
| Pre-S TV - 3wk | -0.25 | -0.33 | -0.17 | -0.36 | -0.53 | -0.18 | -0.22 | -0.36 | -0.08 | -0.18 | -0.28 | -0.08 | 0.160 |
| Pre-S TV - 2mo | -0.35 | -0.45 | -0.25 | -0.46 | -0.67 | -0.24 | -0.37 | -0.55 | -0.18 | -0.24 | -0.33 | -0.14 | 0.166 |
| Basal AV - 3wk | -0.28 | -0.31 | -0.24 | -0.27 | -0.33 | -0.21 | -0.29 | -0.36 | -0.22 | -0.27 | -0.32 | -0.22 | 0.880 |
| Basal IOP - 3mo | 2.34 | 1.32 | 3.36 | 1.58 | 0.00 | 3.17 | 1.74 | 0.33 | 3.14 | 3.52 | 1.41 | 5.64 | 0.221 |
It shows mean changes among basal values and monitoring of each indicator. AT: Average macular thickness in microns; CT: Central foveal thickness in microns; TV: Total macular volume in mm3; Pre-S: Pre-surgery; IOP: Intraocular pressure; AV: Visual acuity; CI: Confidence interval.